Sequencing for Metastatic Clear Cell Renal Cell Carcinoma After Prior Therapy

Insurance and Tolerability Factors Considered in Recurrent RCC Treatment

During a live event, Nizar M. Tannir, MD and participants discussed their takeaways from trial data on recurrent RCC treatment and their personal experiences.

Considering the Impact of Sequencing in Frontline RCC Therapy

During a live event, Nizar M. Tannir, MD and participants discussed how they think ahead to later lines of therapy when choosing frontline regimens for advanced renal cell carcinoma.

Assessing Tivozanib Efficacy in Metastatic RCC Treatment

During a live event, Sumanta K. Pal, MD, discussed lenvatinib dosing and tivozanib efficacy for patients with metastatic renal cell carcinoma.

Evaluating Efficacy of Second-Line RCC Treatments Post-Immunotherapy

During a live event, Sumanta K. Pal, MD, discussed second-line renal cell carcinoma therapies, in the context of a patient with post-immunotherapy progression.

Navigating Second-Line RCC Treatment With Guidelines and Trial Data

During a live event, Chandler H. Park, MD, and participants discuss NCCN guidelines and TiNivo-2 data for second-line renal cell carcinoma.

Second-Line RCC Therapy Depends on Mechanism of Action and Toxicity

During a live event, Chandler H. Park, MD, and event participants looked at quality of life, tolerability, and rechallenging in second-line RCC therapy.

Reviewing Second-Line RCC Therapy After Immune Checkpoint Inhibition

During a live event, Benjamin Garmezy, MD, discussed combinations regimens used for patients with renal cell carcinoma after immune checkpoint inhibitors.

Reviewing RCC Treatment Choices After Progression With IO/TKI

During a live event, Benjamin Garmezy, MD, discussed treatment options in renal cell carcinoma including IO/TKI combinations plus VEGF selectivity.

Navigating Refractory RCC: Insights from the TiNivo-2 Trial

During a live event, Kathryn E. Beckermann, MD, PhD, discussed the treatment of RCC with insights from a recent trial on sequencing targeted therapies.

Beckermann and Participants Discuss Second-Line ccRCC Options

During a Case-Based Roundtable® event, Kathryn E. Beckermann, MD, PhD, discussed second-line regimens with event participants depending on their own practice and trial data for a patient with clear cell renal cell carcinoma.

The Field of Recurrent RCC Regimens Continues to Grow

During a Case-Based Roundtable® event, Sumanta Kumar Pal, MD, discussed regimens for recurrent metastatic clear cell renal cell carcinoma including lenvatinib plus everolimus, belzutifan, and investigational cell therapy and bispecific agents in the second article of a 2-part series.

Long-Term Durability Favors Tivozanib Vs Other TKI in Recurrent mRCC

During a Case-Based Roundtable® event, Sumanta Kumar Pal, MD, discussed long-term outcomes of the TIVO-3 trial in patients with metastatic clear cell renal cell carcinoma in the first article of a 2-part series.

Tolerability Helps Decide Third-Line Treatment in Advanced RCC

During a Case-Based Roundtable® Chandler H. Park, MD, led a discussion on the considerations physicians have when deciding on their treatment approach in the third line for patients with advanced renal cell carcinoma in the first article of a 2-part series.

Tolerability Concerns Influence Use of Lenvatinib/Everolimus Vs Tivozanib in RCC

During a Targeted Oncology™ Case-Based Roundtable™ event, Sumanta K. Pal, MD, and participants explored the third-line treatment options for a patient with advanced renal cell carcinoma. This is the second of 2 articles based on this event.

Peers Discuss Impressions of Tivozanib’s Role as Third-Line RCC Therapy

During a Targeted Oncology™ Case-Based Roundtable™ event, Sumanta K. Pal, MD, discussed the case of an older patient with metastatic renal cell carcinoma who had recurrent disease after receiving axitinib and pembrolizumb, then single-agent cabozantinib. This is the first of 2 articles based on this event.

Key Efficacy and Tolerability Factors for Later-Line Therapies in RCC

During a Targeted Oncology™ Case-Based Roundtable™ event, Arnab Basu, MD, MPH, and participants discussed issues related to the use of tivozanib and lenvatinib/everolimus as third-line therapies for patients with advanced renal cell carcinoma.

Sequencing Choices from First- to Third-Line Regimens in ccRCC

During a Targeted Oncology™ Case-Based Roundtable™ event, Arnab Basu, MD, MPH, asked participants about what sequence of therapies they would use in the first, second, and third lines for a patient with metastatic clear cell renal cell carcinoma. This is the first of 2 articles based on this event.

Assessing Second- and Third- Line Therapies in Advanced RCC

In the second article of a 2-part series, Sumanta K. Pal, MD, leads a discussion on what therapies physicians consider in the later-line settings for treatment of patients with advanced renal cell carcinoma.

Choosing Between Tivozanib and Lenvatinib/Everolimus in Third-Line RCC

During a Targeted Oncology™ Case-Based Roundtable™ event, Randy F. Sweis, MD, discussed with participants their experiences using tivozanib and lenvatinib/everolimus in patients who have received at least 2 prior lines of therapy for advanced renal cell carcinoma. This is the second of 2 articles based on this event.

Use of Immunotherapy Considered in Later Lines of RCC Therapy

During a Targeted Oncology™ Case-Based Roundtable™ event, Randy F. Sweis, MD, discussed possible therapy options for a patient with metastatic renal cell carcinoma whose disease progressed on frontline therapy.

Factors for Selecting Later-Line Therapies in Advanced RCC

Chung-Han Lee, MD, PhD, discusses the most important factors in treatment selection for later-line therapy in renal cell carcinoma.

Lenvatinib/Everolimus Vs Tivozanib Evaluated for Later-Line RCC

Benjamin Garmezy, MD, discusses the choice of third-line therapies in patients with advanced renal cell carcinoma.

Factors Favoring Tivozanib as Third-Line Therapy for Advanced RCC

During a Targeted Oncology case-based roundtable event, Saby George, MD, and participants discussed the role of tivozanib and other later-line options in patients with advanced renal cell carcinoma.

Second-Line Considerations After Immune Toxicity From Prior RCC Therapy

During a Targeted Oncology case-based roundtable event, Saby George, MD, discussed which second-line therapy would be appropriate for a patient who discontinued frontline immunotherapy/tyrosine kinase inhibitor therapy due to immune-related toxicity.

Reviewing Efficacy and Tolerability in TIVO-3 Trial of Tivozanib for RCC

During a Targeted Oncology case-based roundtable event, Randy F. Sweis, MD, discussed the results of the TIVO-3 trial of tivozanib. This is the second of 2 articles based on this event.

Discussing Tolerability of Tivozanib as Third-Line Therapy for mRCC

During a Targeted Oncology case-based roundtable event, Randy F. Sweis, MD, discussed with participants their experience with the tolerability of tivozanib for recurrent advanced renal cell carcinoma. This is the first of 2 articles based on this event.

Tivozanib Shows Efficacy and Safety in Heavily Pretreated ccRCC

Helen H. Moon, MD, discusses the results of the TIVO-3 trial of tivozanib for patients with recurrent clear cell renal cell carcinoma.